Stocks · News reference

Arrowhead Achieves Clinical Validation for New Drug Platform

Sep 16, 2026, 11:39 AMVandana Singh

Arrowhead Pharmaceuticals reports interim Phase 1/2a data for ARO-DIMER-PA, demonstrating dual-gene silencing to treat high fat in blood.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Sep 16, 2026, 11:39 AM
Checked: Sep 16, 2026, 11:39 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 15, 2026, 6:23 PMBenzinga Newsdesk
Arrowhead Pharmaceuticals shares are trading lower. The company announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, RNAi therapeutic dimer for the treatment of mixed hyperlipidemia.
ARWR
BenzingaSep 15, 2026, 5:27 PMPiero Cingari
10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today
The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi pipeline outages, pressuring stocks ahead of the Fed.
APA ARWR ASND CAI CAVA
BenzingaSep 15, 2026, 11:31 AMBenzinga Newsdesk
Arrowhead Pharmaceuticals Says Phase 1/2a Interim Single-Dose Data For ARO-DIMER-PA Showed Mean Maximal Reductions Of 54% In Bad Cholesterol, 73% In Triglycerides; No Drug-Related Serious Adverse Events
ARWR